4.3 Article

The Effect of the Acute Submaximal Exercise on Thrombin Activatable Fibrinolysis Inhibitor Levels in Young Sedentary Males

期刊

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
卷 17, 期 4, 页码 414-420

出版社

SAGE PUBLICATIONS INC
DOI: 10.1177/1076029610385672

关键词

Exercise; coagulation; fibrinolysis; male

向作者/读者索取更多资源

Depending on type, duration, and intensity of the exercise, changes occur in hemostasis. In this study, we evaluated the changes in the parameters of coagulation and fibrinolytic systems that happened after the submaximal aerobic exercises by bicycle ergomater. Twelve healthy male participants whose ages were between 21 and 28 have been included. The venous samples have been drawn before the exercise as well as at the 0th, 15th, and 60th minutes after the submaximal exercise. The values of prothrombin time (PT), active partial thromboplastin time (aPTT), D-dimer, fibrinogen, plasminogen activator inhibitor 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) have been measured. Plasminogen activator inhibitor 1 values have shown an insignificant increase after exercise (P = .328), whereas, it has decreased significantly during the resting period (P = .033) Postexercise 15th and 60th minutes TAFI values have decreased significantly comparing to basal and postexercise (0th minute) values (P = .001). Fibrinolytic system activation is observed after acute submaximal aerobic exercise of sedentary healthy participants.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Hematology

A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

Alessandra Tedeschi, Richard Greil, Fatih Demirkan, Tadeusz Robak, Carol Moreno, Paul M. Barr, Bertrand Anz, David Simpson, Gianluca Gaidano, Osnat Bairey, Don Stevens, Devinder Gill, Ian W. Flinn, Thomas J. Kipps, Jan A. Burger, Jennifer Lin, Thomas Webb, Viktor Fedorov, Lori Styles, John G. Gribben

HAEMATOLOGICA (2020)

Article Oncology

Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

Graeme A. M. Fraser, Asher Chanan-Khan, Fatih Demirkan, Rodrigo Santucci Silva, Sebastian Grosicki, Ann Janssens, Jiri Mayer, Nancy L. Bartlett, Marie-Sarah Dilhuydy, Javier Loscertales, Abraham Avigdor, Simon Rule, Olga Samoilova, Miguel A. Pavlovsky, Andre Goy, Anthony Mato, Michael Hallek, Mariya Salman, Monelle Tamegnon, Steven Sun, Anne Connor, Kerri Nottage, Natasha Schuier, Sriram Balasubramanian, Angela Howes, Paula Cramer

LEUKEMIA & LYMPHOMA (2020)

Article Medicine, Research & Experimental

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

Ajai Chari, Markus Munder, Katja Weisel, Matthew Jenner, Ceri Bygrave, Maria Teresa Petrucci, Mario Boccadoro, Michele Cavo, Niels W. C. J. van de Donk, Mehmet Turgut, Fatih Demirkan, Ihsan Karadogan, Edward Libby, Robert Kleiman, Steven Kuppens, Rajesh Bandekar, Tobias Neff, Christoph Heuck, Ming Qi, Pamela L. Clemens, Hartmut Goldschmidt

Summary: The study on daratumumab showed a small but clinically insignificant effect on ECG intervals and concentration-QTc relationships.

ADVANCES IN THERAPY (2021)

Article Genetics & Heredity

Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?

Beyhan Durak Aras, Sevgi Isik, Hava Uskudar Teke, Abdulvahap Aslan, Filiz Yavasoglu, Zafer Gulbas, Fatih Demirkan, Hulya Ozen, Oguz Cilingir, Nur Sena Inci, Gulcin Gunden, Tuba Bulduk, Ebru Erzurumluoglu Gokalp, Sinem Kocagil, Sevilhan Artan, Olga Meltem Akay

Summary: The study found no significant association between RB1 deletion and TTFT, stage, and OS, but there was a significant association between high del(13q) and TTFT. The deletion burden may have an impact on prognosis.

MOLECULAR CYTOGENETICS (2021)

Article Hematology

Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study

Richard Greil, Alessandra Tedeschi, Carol Moreno, Bertrand Anz, Loree Larratt, Martin Simkovic, Devinder Gill, John G. Gribben, Ian W. Flinn, Zhengyuan Wang, Leo W. K. Cheung, Aaron N. Nguyen, Cathy Zhou, Lori Styles, Fatih Demirkan

Summary: In a study comparing ibrutinib-obinutuzumab and chlorambucil-obinutuzumab treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma, it was found that ibrutinib could reduce the incidence of infusion-related reactions and lower the levels of inflammatory cytokines. Elevated levels of IL-6 and IL-8 were associated with the occurrence of IRRs, supporting the immunomodulatory mechanism of action for ibrutinib.

ANNALS OF HEMATOLOGY (2021)

Article Hematology

Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy

Serhat celik, Leylagul Kaynar, Zeynep Tugba Guven, Mustafa Baydar, Muzaffer Keklik, Mustafa cetin, Ali Unal, Fatih Demirkan

Summary: Secondary hypogammaglobulinemia (SHG) is a common complication of CLL patients receiving ibrutinib treatment, leading to decreased IgG levels. Patients with SHG had higher rates of adverse effects but also higher rates of complete and partial remission compared to those without SHG. Overall survival (OS) and progression free survival (PFS) were not significantly different between the two groups.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2022)

Article Hematology

Therapeutic plasma exchange in neurological diseases: Eleven years experience at a tertiary care center in Turkey

Ahmet Seyhanli, Boran Yavuz, Ismail Selimoglu, Ihsan Sukru Sengun, Abdullah Taha Aslan, Guner Hayri Ozsan, Inci Alacacioglu, Fatih Demirkan

Summary: The study found that between 2008 and 2019, the most common indication for TPE was Myasthenia-Gravis syndrome (34.7%) among 207 patients who underwent 1459 TPE procedures. The overall complication rate for TPE was 1.6%, with allergic reactions (5.3%) and hypotension (2.9%) being the most commonly reported adverse events. In experienced hands, TPE was shown to be safe and manageable with low complication rates.

THERAPEUTIC APHERESIS AND DIALYSIS (2022)

Article Hematology

Evaluation of using fresh frozen plasma for patients with cirrhosis at a tertiary healthcare center in Turkey: Strict transfusion policies are essential

Ahmet Seyhanli, Yazgulu Cansu Ozkan, Goksel Bengi, Inci Alacacioglu, Guner Hayri Ozsan, Fatih Demirkan

Summary: This study evaluated FFP transfusions in patients with cirrhosis and found a significant proportion of inappropriate use, mainly for correcting prolonged INR. Regular utilization reviews and formal education programs are important to avoid inappropriate FFP usage and improve transfusion management quality.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Article Oncology

Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies

Jan A. Burger, Tadeusz Robak, Fatih Demirkan, Osnat Bairey, Carol Moreno, David Simpson, Talha Munir, Don A. Stevens, Sandra Dai, Leo W. K. Cheung, Kevin Kwei, Indu Lal, Emily Hsu, Thomas J. Kipps, Alessandra Tedeschi

Summary: This study found that first-line ibrutinib-based therapy can improve outcomes in chronic lymphocytic leukemia, regardless of high-risk genomic features.

LEUKEMIA & LYMPHOMA (2022)

Article Biochemistry & Molecular Biology

Hemodynamic changes in athletes' brains: is there any adaptation

Egemen Manci, Ozan C. Deniz, Cagdas Guducu, Erkan Gunay, Cem S. Bediz

Summary: By comparing sedentary individuals and athletes, this study found that athletes showed better performance and faster recovery of hemodynamic changes in the prefrontal cortex during sprint interval training and recovery periods, despite increased fatigue.

GENERAL PHYSIOLOGY AND BIOPHYSICS (2021)

Meeting Abstract Oncology

Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.

Mary Ann Anderson, Matthew Steven Davids, Arnon P. Kater, Tara Cochrane, Fatih Demirkan, Yair Herishanu, Brian Leber, Eugene Nikitin, Abdullah A. Masud, Tanya S. Rosenberg, Simon Sharmokh, Stan Fort, Francesco Forconi

JOURNAL OF CLINICAL ONCOLOGY (2020)

Meeting Abstract Hematology

Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Jan A. Burger, Tadeusz Robak, Fatih Demirkan, Osnat Bairey, Carol Moreno, David Simpson, Talha Munir, Don A. Stevens, Sandra Dai, Leo W. K. Cheung, Kevin Kwei, Indu Lal, Emily Hsu, Thomas J. Kipps, Alessandra Tedeschi

Meeting Abstract Oncology

Real-World Data from the Turkish National Chronic Lymphocytic Leukemia Registry

Fatih Demirkan, Omur Gokmen Sevindik

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)

Meeting Abstract Oncology

Neutropenia Analysis of Venetoclax Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Pooled Data from VENICE-I and -II Phase 3b Trials

Mary Ann Anderson, Matthew S. Davids, Arnon P. Kater, Tara Cochrane, Fatih Demirkan, Yair Herishanu, Brian Leber, Eugene Nikitin, Abdullah A. Masud, Tanya S. Rosenberg, Simon Sharmokh, Stan Fort, Francesco Forconi

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)

暂无数据